Payment overview · 2025
General Payments
$261.85
7 reported records · 5 companies
Healthcare provider profile · identity verified
Danielle Steinmetz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEVITTOWN, PA · NPI 1982101036
Verified facts
What the public records show
CMS Open Payments records show Danielle Steinmetz, MD received $261.85 in general payments during 2025 across 7 reported records.
Neurocrine BioSciences, Inc. accounted for 60.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $158.82 | 60.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.31 | 13.5% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $30.99 | 11.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.81 | 7.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.92 | 6.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $261.85 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $158.82 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $30.99 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 508 | 93 |
| Gabapentin | Gabapentin | 241 | 39 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 49 |
| Furosemide | Furosemide | 207 | 40 |
| Losartan Potassium | Losartan Potassium | 201 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 191 | 43 |
| Eliquis | Apixaban | 187 | 38 |
| Sertraline Hcl | Sertraline Hcl | 137 | 22 |
| Donepezil Hcl | Donepezil Hcl | 135 | 18 |
| Mirtazapine | Mirtazapine | 115 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 20 |
| Trazodone Hcl | Trazodone Hcl | 107 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 20 |
| Memantine Hcl | Memantine Hcl | 101 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 20 |
| Potassium Chloride | Potassium Chloride | 97 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 20 |
| Clonazepam | Clonazepam | 86 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 24 |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Carvedilol | Carvedilol | 72 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 17 |
| Januvia | Sitagliptin Phosphate | 67 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 18 |
| Tramadol Hcl | Tramadol Hcl | 65 | 25 |
| Lorazepam | Lorazepam | 64 | 29 |
| Lisinopril | Lisinopril | 59 | 14 |
| Divalproex Sodium | Divalproex Sodium | 58 | suppressed |
| Metformin Hcl | Metformin Hcl | 58 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Famotidine | Famotidine | 53 | 20 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Allopurinol | Allopurinol | 51 | suppressed |
| Ezetimibe | Ezetimibe | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Simvastatin | Simvastatin | 44 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Alprazolam | Alprazolam | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Omeprazole | Omeprazole | 37 | 16 |
| Topiramate | Topiramate | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Cephalexin | Cephalexin | 28 | 15 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 25 | 12 |
| Nystatin | Nystatin | 25 | 17 |
| Phenytek | Phenytoin Sodium Extended | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 19 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 19 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 12 |
| Atenolol | Atenolol | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Xcopri | Cenobamate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Fycompa | Perampanel | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 14 |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Acarbose | Acarbose | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 12 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $261.85 · 7 records | Neurocrine BioSciences, Inc. | INGREZZA, MOUNJARO, NUPLAZID, SPRAVATO, The Cologuard Plus Collection Kit, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Janssen Pharmaceuticals, Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error